|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61P 35/04 | |
| A61K 38/17 |
| (11) | Number of the document | 2111229 |
| (13) | Kind of document | T |
| (96) | European patent application number | 08725118.7 |
| Date of filing the European patent application | 2008-02-01 | |
| (97) | Date of publication of the European application | 2009-10-28 |
| (45) | Date of publication and mention of the grant of the patent | 2013-04-10 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2008/001429 |
| Date | 2008-02-01 |
| (87) | Number | WO 2008/094708 |
| Date | 2008-08-07 |
| (30) | Number | Date | Country code |
| 899070 P | 2007-02-01 | US | |
| 540 P | 2007-10-25 | US |
| (72) |
KNOPF, John, US
SEEHRA, Jasbir, US
KUMAR, Ravindra, US
|
| (73) |
Acceleron Pharma, Inc.,
128 Sidney Street, Cambridge, MA 02139,
US
|
| (54) | Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss |
| Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss |